Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Peru-15 (Choleragarde) with Measles Vaccine in Infants
NCT00624975Phase 2Terminated
- Sponsor
- International Vaccine Institute
- Start
- Nov 2008
- Primary completion
- Jul 2012
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Peru-15 vaccine in cholera (2 arms), sponsored by International Vaccine Institute. Primary endpoints: Proportion of subjects with adverse events at 28 days, Proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies at 1 week and 1 more. Started Nov 2008; status: terminated.
02
Drugs
Peru-15 vaccine
03
Conditions
cholera
Beyond the preview
Go deeper on NCT00624975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00624975.